Hydroxytyrosol Supplementation Modifies Plasma Levels of Tissue Inhibitor of Metallopeptidase 1 in Women with Breast Cancer
MetadatosAfficher la notice complète
AuteurRamírez Tortosa, César Luis; Sánchez, Ana; Pérez Ramírez, Cristina; Quiles Morales, José Luis; Robles Almazan, María; Pulido Moran, Mario; Sánchez Rovira, Pedro; Ramírez Tortosa, María Carmen
HydroxytyrosolAntioxidantsExtra-virgin olive oilTIMP-1Breast cancer MMP-9
Ramirez-Tortosa, C., Sanchez, A., Perez-Ramirez, C., Quiles, J. L., Robles-Almazan, M., Pulido-Moran, M., ... & Ramirez-Tortosa, M. (2019). Hydroxytyrosol Supplementation Modifies Plasma Levels of Tissue Inhibitor of Metallopeptidase 1 in Women with Breast Cancer. Antioxidants, 8(9), 393. [doi: 10.3390/antiox8090393]
PatrocinadorThis research was funded by Junta de Andalucía, Spain, Servicio Andaluz de Salud: Subvenciones para la financiacion de la Investigación, Desarrollo, e Innovación Biomédica en Ciencias de la Salud en Biomedicina, Grant number PI-0695-2012.
The etiology of breast cancer can be very different. Most antineoplastic drugs are not selective against tumor cells and also affect normal cells, leading to a wide variety of adverse reactions such as the production of free radicals by altering the redox state of the organisms. Therefore, the objective of this study was to elucidate if hydroxytyrosol (HT) (an antioxidant present in extra virgin olive oil) has a chemomodulatory effect when combined with the chemotherapeutic drugs epirubicin and cyclophosphamide followed by taxanes in breast cancer patients. Changes in plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) throughout the chemotherapy treatment were studied. Both molecules are involved in cell proliferation, apoptosis, neoangiogenesis, and metastasis in breast cancer patients. Women with breast cancer were divided into two groups: a group of patients receiving a dietary supplement of HT and a control group of patients receiving placebo. The results showed that the plasma levels of TIMP-1 in the group of patients receiving HT were significantly lower than those levels found in the control group after the epirubicin-cyclophosphamide chemotherapy.